688578 艾力斯
已收盘 09-30 15:00:00
资讯
新帖
简况
9月30日艾力斯涨5.02%,中欧医疗健康混合A基金重仓该股
证券之星 · 09-30 16:35
9月30日艾力斯涨5.02%,中欧医疗健康混合A基金重仓该股
艾力斯涨5.02%,开源证券一个月前给出“买入”评级
证券之星 · 09-30 16:35
艾力斯涨5.02%,开源证券一个月前给出“买入”评级
艾力斯医药科技(688578)9月28日主力资金净买入814.88万元
证券之星 · 09-29
艾力斯医药科技(688578)9月28日主力资金净买入814.88万元
艾力斯医药科技(688578)9月24日主力资金净卖出344.76万元
证券之星 · 09-25
艾力斯医药科技(688578)9月24日主力资金净卖出344.76万元
9月23日艾力斯医药科技涨9.35%,中欧医疗健康混合A基金重仓该股
证券之星 · 09-23
9月23日艾力斯医药科技涨9.35%,中欧医疗健康混合A基金重仓该股
艾力斯医药科技涨9.35%,开源证券一个月前给出“买入”评级
证券之星 · 09-23
艾力斯医药科技涨9.35%,开源证券一个月前给出“买入”评级
艾力斯:伏美替尼新适应症上市申请获得受理
证券之星 · 09-22
艾力斯:伏美替尼新适应症上市申请获得受理
艾力斯:伏美替尼用于EGFR突变NSCLC术后辅助治疗
证券之星 · 09-22
艾力斯:伏美替尼用于EGFR突变NSCLC术后辅助治疗
艾力斯:针对EGFR PACC突变NSCLC的一线治疗国际多中心III期注册临床研究
证券之星 · 09-22
艾力斯:针对EGFR PACC突变NSCLC的一线治疗国际多中心III期注册临床研究
艾力斯(688578.SH):甲磺酸伏美替尼片新适应症上市申请获得受理
智通财经 · 09-21
艾力斯(688578.SH):甲磺酸伏美替尼片新适应症上市申请获得受理
每周股票复盘:艾力斯(688578)将参加科创板半年度业绩说明会
证券之星 · 09-13
每周股票复盘:艾力斯(688578)将参加科创板半年度业绩说明会
每周股票复盘:艾力斯(688578)拟每股派现0.60元(含税)
证券之星 · 08-30
每周股票复盘:艾力斯(688578)拟每股派现0.60元(含税)
艾力斯(688578)披露2026年半年度权益分派实施公告,8月27日股价上涨2.64%
证券之星 · 08-27
艾力斯(688578)披露2026年半年度权益分派实施公告,8月27日股价上涨2.64%
中邮证券:给予艾力斯买入评级
证券之星 · 08-25
中邮证券:给予艾力斯买入评级
每周股票复盘:艾力斯(688578)H1净利增46.57%,拟每10股派6元
证券之星 · 08-23
每周股票复盘:艾力斯(688578)H1净利增46.57%,拟每10股派6元
艾力斯(688578)披露2026年半年度募集资金存放与使用情况,8月19日股价下跌1.99%
证券之星 · 08-19
艾力斯(688578)披露2026年半年度募集资金存放与使用情况,8月19日股价下跌1.99%
艾力斯(688578.SH)发布半年度业绩,归母净利润15.41亿元,同比增长46.57%
智通财经 · 08-19
艾力斯(688578.SH)发布半年度业绩,归母净利润15.41亿元,同比增长46.57%
艾力斯(688578)6月30日股东户数2.1万户,较上期增加3.72%
证券之星 · 08-19
艾力斯(688578)6月30日股东户数2.1万户,较上期增加3.72%
头部三甲亮剑合规,艾力斯伏美替尼等四款大单品被暂停采购三个月
国际金融报 · 08-17
头部三甲亮剑合规,艾力斯伏美替尼等四款大单品被暂停采购三个月
艾力斯:公司尚未收到相关股东关于减持计划的通知
证券之星 · 08-13
艾力斯:公司尚未收到相关股东关于减持计划的通知
加载更多
公司概况
公司名称:
上海艾力斯医药科技股份有限公司
所属行业:
医药制造业
上市日期:
2020-12-02
主营业务:
上海艾力斯医药科技股份有限公司的主营业务是肿瘤靶向创新药的研发、生产和营销。公司的主要产品是甲磺酸伏美替尼片、枸橼酸戈来雷塞片、普拉替尼胶囊。2025年,公司自主研发的1类小分子靶向药物甲磺酸伏美替尼片的核心化合物专利创新技术(吡啶胺基嘧啶衍生物、其制备方法及应用)已荣获国家知识产权局、世界知识产权组织联合颁授的第二十五届中国专利金奖。
发行价格:
22.73
{"stockData":{"symbol":"688578","market":"SH","secType":"STK","nameCN":"艾力斯","latestPrice":111.58,"timestamp":1790751600000,"preClose":106.25,"halted":0,"volume":9574765,"delay":0,"changeRate":0.0502,"floatShares":450000000,"shares":450000000,"eps":5.9526,"marketStatus":"已收盘","change":5.33,"latestTime":"09-30 15:00:00","open":105.5,"high":112.36,"low":105.2,"amount":1057000000,"amplitude":0.0674,"askPrice":111.59,"askSize":238,"bidPrice":111.58,"bidSize":88,"shortable":0,"etf":0,"ttmEps":5.9526,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":106.25,"symbolType":"stock_kcb","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":116.88,"lowLimit":95.63,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":450000000,"isCdr":false,"pbRate":5.93,"roa":"--","peRate":18.74475,"roe":"19.7%","epsLYR":4.86,"committee":0.058663,"marketValue":50211000000,"turnoverRate":0.0213,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-10-08。","afterMarket":{"amount":240789.64,"volume":2158,"close":111.58,"buyVolume":0,"sellVolume":2142,"time":1790753637746,"indexStatus":"已收盘 09-30 15:30:00","preClose":106.25},"floatMarketCap":50211000000},"requestUrl":"/m/hq/s/688578","defaultTab":"news","newsList":[{"id":"2671274261","title":"9月30日艾力斯涨5.02%,中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2671274261","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671274261?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:35","pubTimestamp":1790757319,"startTime":"0","endTime":"0","summary":"证券之星消息,9月30日艾力斯涨5.02%,收盘报111.58元,换手率2.13%,成交量9.57万手,成交额10.57亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共73家,其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为127.36亿元,最新净值1.9547,较上一交易日上涨0.16%,近一年下跌4.01%。中欧医疗健康混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000025796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239","159760"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671740812","title":"艾力斯涨5.02%,开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2671740812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671740812?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:35","pubTimestamp":1790757309,"startTime":"0","endTime":"0","summary":"今日艾力斯涨5.02%,收盘报111.58元。2026年8月23日,开源证券研究员余汝意,聂媛媛发布了对艾力斯的研报《公司信息更新报告:核心产品持续放量,后续管线迎来多重催化》,该研报对艾力斯给出“买入”评级。研报中预计公司2026-2028年归母净利润为30.46/35.04/39.87亿元,当前股价对应PE为17.8/15.5/13.6倍,维持“买入”评级。此外,中邮证券研究员盛丽华,陈灿,长城国瑞证券研究员胡晨曦近期也对该股发布了研报,同样给出“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000025794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671661932","title":"艾力斯医药科技(688578)9月28日主力资金净买入814.88万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671661932","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671661932?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:20","pubTimestamp":1790641249,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月28日收盘,艾力斯医药科技报收于105.99元,上涨1.7%,换手率1.83%,成交量8.22万手,成交额8.65亿元。近5日资金流向一览见下表:艾力斯医药科技融资融券信息显示,融资方面,当日融资买入3857.77万元,融资偿还9795.05万元,融资净偿还5937.27万元。艾力斯医药科技主营业务:专注于肿瘤治疗领域的创新药企业,目前已在非小细胞肺癌小分子靶向药领域构建了优势研发管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900007064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","BK0239","688578","BK1574","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670419954","title":"艾力斯医药科技(688578)9月24日主力资金净卖出344.76万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670419954","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670419954?lang=zh_cn&edition=full","pubTime":"2026-09-25 08:22","pubTimestamp":1790295752,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月24日收盘,艾力斯医药科技报收于104.22元,下跌7.29%,换手率2.14%,成交量9.65万手,成交额10.26亿元。近5日资金流向一览见下表:艾力斯医药科技融资融券信息显示,融资方面,当日融资买入1.22亿元,融资偿还8534.22万元,融资净买入3647.45万元。艾力斯医药科技主营业务:专注于肿瘤治疗领域的创新药企业,目前已在非小细胞肺癌小分子靶向药领域构建了优势研发管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092500005077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","688578","09939","BK1515","BK1574","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669109932","title":"9月23日艾力斯医药科技涨9.35%,中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669109932","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669109932?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:38","pubTimestamp":1790152708,"startTime":"0","endTime":"0","summary":"证券之星消息,9月23日艾力斯医药科技涨9.35%,收盘报112.42元,换手率2.97%,成交量13.36万手,成交额14.68亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共73家,其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300028209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","BK1574","688578","159760","09939","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669109183","title":"艾力斯医药科技涨9.35%,开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669109183","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669109183?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:38","pubTimestamp":1790152701,"startTime":"0","endTime":"0","summary":"今日艾力斯医药科技涨9.35%,收盘报112.42元。2026年8月23日,开源证券研究员余汝意,聂媛媛发布了对艾力斯的研报《公司信息更新报告:核心产品持续放量,后续管线迎来多重催化》,该研报对艾力斯给出“买入”评级。此外,中邮证券研究员盛丽华,陈灿,长城国瑞证券研究员胡晨曦近期也对该股发布了研报,同样给出“买入”评级。艾力斯医药科技个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300028203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","09939","161027","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669117261","title":"艾力斯:伏美替尼新适应症上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2669117261","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669117261?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:51","pubTimestamp":1790067071,"startTime":"0","endTime":"0","summary":"艾力斯医药科技回复:尊敬的投资者您好,受理号“CXHS2600135”为伏美替尼用于具有表皮生长因子受体外显子19缺失或外显子21置换突变的非小细胞肺癌成人患者肿瘤切除术后的辅助治疗新适应症上市申请,相关信息属于自愿性信息披露公告。公司始终严格按照相关法律法规要求及时履行信息披露义务,具体情况可参考公司于2026年9月22日披露的《上海艾力斯医药科技股份有限公司自愿披露关于甲磺酸伏美替尼片新适应症上市申请获得受理的公告》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200028913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669174921","title":"艾力斯:伏美替尼用于EGFR突变NSCLC术后辅助治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2669174921","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669174921?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:48","pubTimestamp":1790066894,"startTime":"0","endTime":"0","summary":"9月20日受理号为CXHS2600135的甲磺酸伏美替尼片是用于什么适应症,是否纳入优先审评。另原计划9月提请IND的大分子药,能否如期。艾力斯医药科技回复:尊敬的投资者您好,受理号“CXHS2600135”为伏美替尼用于具有表皮生长因子受体外显子19缺失或外显子21置换突变的非小细胞肺癌成人患者肿瘤切除术后的辅助治疗新适应症上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200028842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669611741","title":"艾力斯:针对EGFR PACC突变NSCLC的一线治疗国际多中心III期注册临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2669611741","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669611741?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:45","pubTimestamp":1790066711,"startTime":"0","endTime":"0","summary":"贵公司一直讲针对 EGFR PACC 突变 NSCLC 的一线治疗国际多中心 III 期注册临床研究,最终分析需要达到预设的事件数,作为该临床研究的出资方之一,应该不会光出钱,也能掌握所谓预设的事件的真正内涵,能否披露一下。艾力斯医药科技回复:尊敬的投资者您好,针对EGFR PACC突变NSCLC的一线治疗国际多中心III期注册临床研究,由ArriVent发起,公司负责该研究的国内临床运营。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200028757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669152388","title":"艾力斯(688578.SH):甲磺酸伏美替尼片新适应症上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2669152388","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669152388?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:56","pubTimestamp":1789984588,"startTime":"0","endTime":"0","summary":"智通财经APP讯,艾力斯 发布公告,近日,公司收到国家药品监督管理局核准签发的《受理通知书》,公司递交的甲磺酸伏美替尼片用于具有表皮生长因子受体外显子19缺失或外显子21置换突变的非小细胞肺癌成人患者肿瘤切除术后的辅助治疗新适应症上市申请获得受理。多项临床研究结果显示,伏美替尼具有明确的抗肿瘤疗效和良好的安全性特征,患者长期服用接受度高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","IPOS","688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507387","title":"每周股票复盘:艾力斯(688578)将参加科创板半年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507387","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507387?lang=zh_cn&edition=full","pubTime":"2026-09-13 01:39","pubTimestamp":1789234749,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘,艾力斯报收于99.49元,较上周的110.55元下跌10.0%。本周,艾力斯9月7日盘中最高价报110.99元。本周关注点公司公告汇总:艾力斯将于2026年9月16日参加科创板半年度创新药行业集体业绩说明会公司公告汇总上海艾力斯医药科技股份有限公司将于2026年9月16日15:00-17:00参加由上海证券交易所主办的科创板2026年半年度创新药行业集体业绩说明会,通过上证路演中心网络互动方式,就公司2026年半年度经营成果、财务状况等与投资者进行交流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010176","title":"每周股票复盘:艾力斯(688578)拟每股派现0.60元(含税)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010176","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663010176?lang=zh_cn&edition=full","pubTime":"2026-08-30 03:23","pubTimestamp":1788031389,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘,艾力斯报收于113.7元,较上周的116.5元下跌2.4%。本周,艾力斯8月24日盘中最高价报118.86元。8月25日盘中最低价报110.69元。艾力斯当前最新总市值511.65亿元,在化学制药板块市值排名9/149,在两市A股市值排名405/5211。分派对象为截至股权登记日在中证登上海分公司登记在册的全体股东。部分股东红利由公司自行发放,其余通过中证登上海分公司派发。依据相关规定,对不同股东实施差别化税收政策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001091.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662670549","title":"艾力斯(688578)披露2026年半年度权益分派实施公告,8月27日股价上涨2.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662670549","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662670549?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:23","pubTimestamp":1787826185,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘,艾力斯报收于115.05元,较前一交易日上涨2.64%,最新总市值为517.72亿元。该股当日开盘111.55元,最高115.16元,最低110.79元,成交额达5.18亿元,换手率为1.02%。公司于近日披露《上海艾力斯医药科技股份有限公司2026年半年度权益分派实施公告》。股权登记日为2026年9月1日,除权(息)日为2026年9月2日,现金红利发放日为2026年9月2日。分派对象为截至股权登记日在中国证券登记结算有限责任公司上海分公司登记在册的全体股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700044320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662678583","title":"中邮证券:给予艾力斯买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662678583","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662678583?lang=zh_cn&edition=full","pubTime":"2026-08-25 12:21","pubTimestamp":1787631682,"startTime":"0","endTime":"0","summary":"中邮证券有限责任公司盛丽华,陈灿近期对艾力斯进行研究并发布了研究报告《盈利能力再创新高,静待海外数据读出》,给予艾力斯买入评级。公司深耕肺癌市场,商业化成绩显著,考虑伏美替尼仍有20外插与辅助治疗等适应症拓展空间,维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有8家机构给出评级,买入评级8家。本文数据来源于中邮证券有限责任公司,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500024111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661211465","title":"每周股票复盘:艾力斯(688578)H1净利增46.57%,拟每10股派6元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661211465","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661211465?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:17","pubTimestamp":1787422628,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘,艾力斯报收于116.5元,较上周的120.4元下跌3.24%。本周,艾力斯8月20日盘中最高价报122.86元。艾力斯当前最新总市值524.25亿元,在化学制药板块市值排名8/149,在两市A股市值排名392/5210。本周关注点来自业绩披露要点:艾力斯2026年上半年归母净利润15.41亿元,同比上升46.57%。股本股东变化截至2026年6月30日,艾力斯股东户数为2.1万户,较3月31日增加754户,增幅3.72%。户均持股数量由2.22万股降至2.14万股,户均持股市值为233.57万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660842952","title":"艾力斯(688578)披露2026年半年度募集资金存放与使用情况,8月19日股价下跌1.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660842952","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660842952?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:09","pubTimestamp":1787148555,"startTime":"0","endTime":"0","summary":"截至2026年8月19日收盘,艾力斯报收于116.48元,较前一交易日下跌1.99%,最新总市值为524.16亿元。该股当日开盘118.0元,最高120.08元,最低115.75元,成交额达9.19亿元,换手率为1.74%。近日,上海艾力斯医药科技股份有限公司披露《2026年半年度募集资金存放、管理与实际使用情况的专项报告》。公告显示,截至2026年6月30日,募集资金账户余额为4,411.92万元,本年度使用募集资金3,343.81万元,累计使用募集资金总额155,303.42万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900042944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660344444","title":"艾力斯(688578.SH)发布半年度业绩,归母净利润15.41亿元,同比增长46.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660344444","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660344444?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:11","pubTimestamp":1787134304,"startTime":"0","endTime":"0","summary":"智通财经APP讯,艾力斯 披露2026年半年度报告,报告期公司实现营业收入33.2亿元,同比增长39.85%;归属于上市公司股东的净利润15.41亿元,同比增长46.57%;归属于上市公司股东的扣除非经常性损益的净利润13.67亿元,同比增长50.99%;基本每股收益3.42元;公司拟每10股派发现金红利6元(含税)。业绩增长主要原因是报告期内公司积极发挥商业化产品的协同效应,形成多层次的发展动力,充分发挥公司在肿瘤领域的平台优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660644106","title":"艾力斯(688578)6月30日股东户数2.1万户,较上期增加3.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660644106","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660644106?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:02","pubTimestamp":1787133762,"startTime":"0","endTime":"0","summary":"证券之星消息,近日艾力斯披露,截至2026年6月30日公司股东户数为2.1万户,较3月31日增加754.0户,增幅为3.72%。在化学制药行业个股中,艾力斯股东户数低于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.64万户。从股价来看,2026年3月31日至2026年6月30日,艾力斯区间涨幅为14.52%,在此期间股东户数增加754.0户,增幅为3.72%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900031521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660102952","title":"头部三甲亮剑合规,艾力斯伏美替尼等四款大单品被暂停采购三个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2660102952","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660102952?lang=zh_cn&edition=full","pubTime":"2026-08-17 13:40","pubTimestamp":1786945200,"startTime":"0","endTime":"0","summary":"业内人士认为,湘雅二医院本次对四家药企同时开出停采罚单,向全行业传递了零容忍的清晰态度:无论企业规模大小、是否为跨国巨头,只要触碰诊疗区域违规拜访的红线,都将直接面临核心大单品院内停采的严厉处罚。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843021289.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843021289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659329132","title":"艾力斯:公司尚未收到相关股东关于减持计划的通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2659329132","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659329132?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:15","pubTimestamp":1786608910,"startTime":"0","endTime":"0","summary":"证券之星消息,艾力斯(688578)08月13日在投资者关系平台上答复投资者关心的问题。投资者提问:据往年规律,又到了公布减持的时间窗口,近期网上充斥着小道消息说公司大股东拟坚持,已经影响到艾力斯股价,请董秘核实。艾力斯回复:尊敬的投资者您好,公司尚未收到相关股东关于减持计划的通知,若未来涉及相关事项,公司将严格按照相关法律法规的规定及时履行信息披露义务。感谢您的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。相关 ETF责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300025008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790918216184,"stockEarnings":[{"period":"1week","weight":-0.0075},{"period":"1month","weight":0.0075},{"period":"3month","weight":-0.1426},{"period":"6month","weight":0.1592},{"period":"1year","weight":0.0246},{"period":"ytd","weight":0.0846}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海艾力斯医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"21039人(较上一季度增加3.72%)","perCapita":"21388股","listingDate":"2020-12-02","address":"上海市浦东新区周浦镇凌霄花路268号","registeredCapital":"45000万元","survey":" 上海艾力斯医药科技股份有限公司的主营业务是肿瘤靶向创新药的研发、生产和营销。公司的主要产品是甲磺酸伏美替尼片、枸橼酸戈来雷塞片、普拉替尼胶囊。2025年,公司自主研发的1类小分子靶向药物甲磺酸伏美替尼片的核心化合物专利创新技术(吡啶胺基嘧啶衍生物、其制备方法及应用)已荣获国家知识产权局、世界知识产权组织联合颁授的第二十五届中国专利金奖。","listedPrice":22.73},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾力斯(688578)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾力斯(688578)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾力斯,688578,艾力斯股票,艾力斯股票老虎,艾力斯股票老虎国际,艾力斯行情,艾力斯股票行情,艾力斯股价,艾力斯股市,艾力斯股票价格,艾力斯股票交易,艾力斯股票购买,艾力斯股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾力斯(688578)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾力斯(688578)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}